Literature DB >> 29692218

Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.

Twisha S Patel1, Jason M Pogue2, John P Mills3, Keith S Kaye3.   

Abstract

Meropenem-vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE). The efficacy of meropenem-vaborbactam for the treatment of complicated urinary tract infections and acute pyelonephritis was demonstrated in a Phase III trial (TANGO I). Preliminary data from TANGO II, a separate Phase III study, support the efficacy of meropenem-vaborbactam for the treatment of infections caused by CRE. Overall, meropenem-vaborbactam appears to be safe and well tolerated. It has favorable toxicity, pharmacokinetic and pharmacodynamic profiles compared with other antibiotics with activity against CRE. Meropenem-vaborbactam is an important addition to the current armamentarium of antimicrobial agents with activity against K. pneumoniae carbapenemase-producing CRE.

Entities:  

Keywords:  Gram-negative; Klebsiella pneumoniae carbapenemase; carbapenem; carbapenem-resistant Enterobacteriaceae; meropenem and vaborbactam; β-lactam; β-lactamase; β-lactamase inhibitor

Mesh：

Substances：

Year:  2018        PMID： 29692218      PMCID： PMC6161103          DOI： 10.2217/fmb-2018-0054

Source DB:  PubMed          Journal:  Future Microbiol        ISSN： 1746-0913            Impact factor:   3.165


  36 in total

1.  Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.

Authors:  Christopher M Rubino; Sujata M Bhavnani; Jeffery S Loutit; Brooke Lohse; Michael N Dudley; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 2.  Meropenem, a new carbapenem antibiotic.

Authors:  D N Fish; T J Singletary
Journal:  Pharmacotherapy       Date:  1997 Jul-Aug       Impact factor: 4.705

3.  Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.

Authors:  Christine T Ong; Pamela R Tessier; Chonghua Li; Charles H Nightingale; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2006-08-23       Impact factor: 2.803

Review 4.  Molecular mechanisms of β-lactam resistance in Streptococcus pneumoniae.

Authors:  Regine Hakenbeck; Reinhold Brückner; Dalia Denapaite; Patrick Maurer
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

5.  Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Brian A Potoski; Rachel V Marini; Yohei Doi; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.

Authors:  Romney M Humphries; Shangxin Yang; Peera Hemarajata; Kevin W Ward; Janet A Hindler; Shelley A Miller; Aric Gregson
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

7.  Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.

Authors:  Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

Review 8.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 9.  Pharmacokinetic and pharmacodynamic properties of meropenem.

Authors:  David P Nicolau
Journal:  Clin Infect Dis       Date:  2008-09-15       Impact factor: 9.079

10.  Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.

Authors:  Mariana Castanheira; Paul R Rhomberg; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191
View more
  7 in total

Review 1.  Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review.

Authors:  Julie Gorham; Fabio Silvio Taccone; Maya Hites
Journal:  Antibiotics (Basel)       Date:  2022-04-20

2.  New β-Lactam Antibiotics and Ceragenins - A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of Pseudomonas aeruginosa.

Authors:  Paulina Paprocka; Bonita Durnaś; Angelika Mańkowska; Karol Skłodowski; Grzegorz Król; Magdalena Zakrzewska; Michał Czarnowski; Patrycja Kot; Kamila Fortunka; Stanisław Góźdź; Paul B Savage; Robert Bucki
Journal:  Infect Drug Resist       Date:  2021-12-25       Impact factor: 4.003

3.  Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections.

Authors:  Matteo Bassetti; Javier Garau
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

Review 4.  Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects.

Authors:  Glenn T Werneburg
Journal:  Res Rep Urol       Date:  2022-04-04

Review 5.  Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management.

Authors:  Elena Xu; David Pérez-Torres; Paraskevi C Fragkou; Jean-Ralph Zahar; Despoina Koulenti
Journal:  Microorganisms       Date:  2021-03-05

Review 6.  Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors.

Authors:  Giacomo Luci; Francesca Mattioli; Marco Falcone; Antonello Di Paolo
Journal:  Antibiotics (Basel)       Date:  2021-06-24

Review 7.  Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Elena-Georgiana Dobre; Ilda Czobor Barbu; Roxana Elena Cristian; Marcela Popa; Sang Hee Lee; Carmen Limban; Ilinca Margareta Vlad; Mariana Carmen Chifiriuc
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 6.208
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.